We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Microfluidic Device Created For Genetic Analysis

By LabMedica International staff writers
Posted on 17 Aug 2011
A silicone chip based apparatus has been generated that could make genetic analysis far more sensitive, rapid, and cost-effective. More...


The device, which is about the size of a nine-volt battery, allows simultaneously analysis of 300 individual cells by routing fluid carrying cells through microscopic tubes and valves.

Scientists at the University of British Columbia, (UBC; Vancouver, BC, Canada) isolated the cells into their separate chambers, and then extracted and replicated the cells' ribonucleic acid (RNA) for further analysis. The device's ease of use and cost-effectiveness arise from its integration of almost the entire process of cell analysis, not just separating the cells, but also mixing them with chemical reagents to highlight their genetic code and analyzing the results by measuring fluorescent light emitted from the reaction. All of that can now be done on the chip.

The fully integrated microfluidic device is capable of performing high-precision real-time quantitative polymerase chain reaction (RT-qPCR) measurements of gene expression from hundreds of single cells per run. The device executes all steps of single-cell processing, including cell capture, cell lysis, reverse transcription, and quantitative PCR. By enabling such "single-cell analysis," the device could accelerate genetic research and hasten the use of far more detailed tests for diagnosing cancer. The standard genetic tests, which require large numbers of cells, capture only an average composite picture of thousands or millions of different cells that may obscure their true nature and the interactions between them.

Carl Hansen, PhD, an assistant professor at UCB said, "This technology and other approaches like it could radically change the way we do both basic and applied biomedical research, and would make single-cell analysis a more plausible option for treating patients, allowing clinicians to distinguish various cancers from one another and tailor their treatments accordingly." The study was published August 1, 2011, in the Proceedings of the National Academy of Sciences of the United States of America (PNAS).

Related Links:

University of British Columbia




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: Shutterstock

Blood Test Could Guide Drug Selection to Prevent Repeat Heart Attacks and Strokes

Secondary prevention after myocardial infarction or stroke relies on antiplatelet therapy, yet responses vary widely and both recurrent thrombosis and bleeding remain persistent risks. In the United Kingdom,... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Type 1 diabetes affects more than 9 million people worldwide and can begin years before symptoms appear, making early identification of at-risk children difficult (Image Credit: iStock)

Early-Life Gut Microbiome Changes May Help Assess Type 1 Diabetes Risk

Type 1 diabetes (T1D) affects more than 9 million people worldwide, including 1.8 million children and adolescents, and often begins years before symptoms appear. Early identification of children who are... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.